Clinical Trial Update: Protocol to Allow Continued Access of Ficlatuzumab to P05538 Patient

View source ↗

Summary

This document outlines a protocol to provide continued access to ficlatuzumab for a patient (P05538) with Mullerian mixed tumor of the ovary.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mullerian Mixed Tumor of the Ovary

Drugs mentioned

• Ficlatuzumab (ficlatuzumab)

Snippet

Sponsor: AVEO Pharmaceuticals, Inc. | Conditions: Mullerian Mixed Tumor of Ovary | Status: NO_LONGER_AVAILABLE